P-糖蛋白和阿尔茨海默病:威胁和机遇
Joseph Jr Asante1, Steven W Barger2,3,4
1Graduate Program in Bioinformatics, University of Arkansas at Little Rock, Little Rock, AR, USA.
ASN neuro
|April 23, 2025
概括
P-glycoprotein (P-gp) 通过影响大脑中的粉样β (Aβ) 清除,影响阿尔茨海默病 (AD). 调节P-gp功能为AD治疗提供了一个潜在的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,在全球范围内影响着超过5000万人.
- 阿尔茨海默病的一个关键特征是大脑中粉样β (Aβ) 蛋白的积累.
- P-葡萄糖蛋白 (P-gp) 对于通过脑血管内皮从大脑中清除Aβ至关重要.
研究的目的:
- 探索P-糖蛋白 (P-gp) 在阿尔茨海默氏病 (AD) 发病过程中的作用.
- 讨论调节P-gp功能的治疗潜力,用于AD治疗.
- 分析不同的P-gp基质如何影响Aβ流量和大脑清除.
主要方法:
- 对关于P-gp,Aβ和AD的现有文献的审查.
- 对P-gp基质相互作用和补充组的分析.
- 讨论对AD治疗策略的影响.
主要成果:
- 异常的P-gp水平或活性与AD中的Aβ积累有关.
- P-gp的基质结合点可以导致影响Aβ流动的竞争性或合作性相互作用.
- 特定的P-gp基质可能会阻碍或增强大脑中的Aβ清除.
结论:
- P-gp在与AD相关的大脑Aβ清除机制中发挥着重要作用.
- 了解P-gp基质相互作用对于开发有效的AD疗法至关重要.
- 准P-gp代表了新型阿尔茨海默病治疗的有希望的途径.
更多相关视频
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.6K
11:57Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase
Published on: June 24, 2025
733
相关概念视频
Amyloid Fibrils
9.0K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.0K
Alzheimer's Disease: Overview
317
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
317
Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
Dementia
65
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
65
